{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:07:40Z","timestamp":1793210860604,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-12970-8","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T04:01:28Z","timestamp":1728273688000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinicopathological characteristics and prognosis of combined hepatocellular cholangiocarcinoma"],"prefix":"10.1186","volume":"24","author":[{"given":"Yue","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Du","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Jian","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia-Fei","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Xia","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9187-7152","authenticated-orcid":false,"given":"Dan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,7]]},"reference":[{"key":"12970_CR1","unstructured":"International Agency for Research on Cancer (IARC). IARC Global Cancer Observatory. Globocan 2020,March, 2021.https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/160-china-fact-sheets.pdf. Cited 15 July 2023."},{"key":"12970_CR2","unstructured":"World Health Organization. WHO Classification of tumors. 5th ed. Digestive System. Lyon: International Agency for Research on Cancer; 2019.260\u2013264."},{"key":"12970_CR3","doi-asserted-by":"publisher","unstructured":"Aur\u00e9lie Beaufr\u00e8re J C, Val\u00e9rie Paradis .Combined hepatocellular-cholangiocarcinoma: An update Beaufr\u00e8re J Hepatol. 74:5:1212-1224.https:\/\/doi.org\/10.1016\/j.jhep.2021.01.035","DOI":"10.1016\/j.jhep.2021.01.035"},{"key":"12970_CR4","unstructured":"World Health Organization. WHO Classification of tumors. 5th ed. Digestive System. Lyon: International Agency for Research on Cancer; 2019.98."},{"issue":"1","key":"12970_CR5","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","volume":"73","author":"A Lamarca","year":"2020","unstructured":"Lamarca A, Barriuso J, McNamara MG, Valle JW. Molecular targeted therapies: Ready for \u201cprime time\u201d in biliary tract cancer. J Hepatol. 2020;73(1):170\u201385 10.1016\/j.jhep.2020.03.007.","journal-title":"J Hepatol."},{"issue":"6","key":"12970_CR6","doi-asserted-by":"publisher","first-page":"5327","DOI":"10.3390\/ijms24065327","volume":"24","author":"S Hacking","year":"2023","unstructured":"Hacking S, Chou C, Baykara Y, Wang Y, Uzun A, Gamsiz Uzun ED. MMR Deficiency Defines Distinct Molecular Subtype of Breast Cancer with Histone Proteomic Networks. Int J Mol Sci. 2023;24(6):5327 10.3390\/ijms24065327.","journal-title":"Int J Mol Sci."},{"key":"12970_CR7","doi-asserted-by":"publisher","unstructured":"Courtney J. Riedinger ,Paulina J. Haight and Floor J. Backes et al.Epigenetic MMR defect identifies a risk group not accounted for through traditional risk stratification algorithms in endometrial cancer. Front. Oncol. 13:1147657.https:\/\/doi.org\/10.3389\/fonc.2023.1147657","DOI":"10.3389\/fonc.2023.1147657"},{"key":"12970_CR8","doi-asserted-by":"publisher","unstructured":"Bhavya Yarlagadda, Vaishnavi Kamatham, Ashton Ritter, Faisal Shahjehan, Pashtoon M. Kasi.Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma.NPJ Precis Oncol. ,2019, 2019 Aug 19;3:19.https:\/\/doi.org\/10.1038\/s41698-019-0091-4.","DOI":"10.1038\/s41698-019-0091-4"},{"issue":"14","key":"12970_CR9","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.2147\/OTT.S297643","volume":"25","author":"W Yang","year":"2021","unstructured":"Yang W, Sun Y. Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview. Onco Targets Ther. 2021Feb;25(14):1341\u201366.https:\/\/doi.org\/10.2147\/OTT.S297643.","journal-title":"Onco Targets Ther"},{"key":"12970_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11523-022-00942-6","volume":"18","author":"C Neuzillet","year":"2023","unstructured":"Neuzillet C, Artru P, Assenat E, et al. Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective. Targ Oncol. 2023;18:51\u201376.https:\/\/doi.org\/10.1007\/s11523-022-00942-6.","journal-title":"Targ Oncol"},{"key":"12970_CR11","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s41379-020-00728-z","volume":"34","author":"M Alhamar","year":"2021","unstructured":"Alhamar M, Alkamachi B, Mehrotra H, et al. Clinical significance of quantitative categorization of HER2 fluorescent in situ hybridization results in invasive breast cancer patients treated with HER2-targeted agents. Mod Pathol. 2021;34:720\u201334.https:\/\/doi.org\/10.1038\/s41379-020-00728-z.","journal-title":"Mod Pathol"},{"issue":"15","key":"12970_CR12","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.2147\/JIR.S368138","volume":"17","author":"J Sun","year":"2022","unstructured":"Sun J, Li X, Chen P, Gao Y. From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer. J Inflamm Res. 2022Jul;17(15):4061\u201385.https:\/\/doi.org\/10.2147\/JIR.S368138.","journal-title":"J Inflamm Res"},{"key":"12970_CR13","doi-asserted-by":"publisher","unstructured":".Miguel Zugman, Gehan Botrus ,Roberto Carmagnani Pestana and Pedro Luiz Serrano Uson Junior .Precision Medicine Targeting FGFR2 Genomic Alterations in Advanced Cholangiocarcinoma: Current State and Future Perspectives.Front Oncol. ,2022, 2022 Apr 4;12:860453.https:\/\/doi.org\/10.3389\/fonc.2022.860453","DOI":"10.3389\/fonc.2022.860453"},{"issue":"4","key":"12970_CR14","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s119-020-00556-4","volume":"19","author":"O Raevskaya","year":"2020","unstructured":"Raevskaya O, Appelman H, Razumilava N. A Contemporary Approach to Diagnosis and Treatment of Combined Hepatocellular-Cholangiocarcinoma. Curr Hepatol Rep. 2020;19(4):478\u201385https:\/\/doi.org\/10.1007\/s119-020-00556-4.","journal-title":"Curr Hepatol Rep."},{"key":"12970_CR15","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3390\/medicina57050458","volume":"57","author":"A Rizzo","year":"2021","unstructured":"Rizzo A. Targeted Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors. Medicina. 2021;57:458.https:\/\/doi.org\/10.3390\/medicina57050458.","journal-title":"Medicina"},{"key":"12970_CR16","doi-asserted-by":"publisher","unstructured":"Yuanyuan Zheng, Yan Li and Jiao Feng et al. Cellular based immunotherapy for primary liver cancer. J Exp Clin Cancer Res 40, 250 (2021).https:\/\/doi.org\/10.1186\/s13046-021-02030-5","DOI":"10.1186\/s13046-021-02030-5"},{"issue":"1","key":"12970_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13046-022-02340-2","volume":"41","author":"D Liu","year":"2022","unstructured":"Liu D, Heij LR, Czigany Z, et al. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma. J Exp Clin Cancer Res. 2022;41(1):127.https:\/\/doi.org\/10.1186\/s13046-022-02340-2.","journal-title":"J Exp Clin Cancer Res."},{"issue":"12","key":"12970_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.729705","volume":"3","author":"X Zheng","year":"2021","unstructured":"Zheng X, Jin W, Wang S, Ding H. Progression on the Roles and Mechanisms of Tumor-Infiltrating T Lymphocytes in Patients With Hepatocellular Carcinoma. Front Immunol. 2021Sep;3(12): 729705.https:\/\/doi.org\/10.3389\/fimmu.2021.729705.","journal-title":"Front Immunol"},{"issue":"1","key":"12970_CR19","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1038\/s41598-021-83149-5","volume":"11","author":"TH Yu","year":"2021","unstructured":"Yu TH, Chen X, Zhang XH, Zhang EC, Sun CX. Clinicopathological characteristics and prognostic factors for intrahepatic cholangiocarcinoma: a population-based study. Sci Rep. 2021;11(1):3990.https:\/\/doi.org\/10.1038\/s41598-021-83149-5.","journal-title":"Sci Rep."},{"key":"12970_CR20","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00428-017-2211-2","volume":"471","author":"D Jiang","year":"2017","unstructured":"Jiang D, Peng R, Yan X, et al. Synovial sarcoma showing loss of a green signal in SS18 fluorescence in situ hybridization: a clinicopathological and molecular study of 12 cases. Virchows Arch. 2017;471:799\u2013807.https:\/\/doi.org\/10.1007\/s00428-017-2211-2.","journal-title":"Virchows Arch"},{"issue":"16","key":"12970_CR21","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12885-016-2156-x.PMID:26917546;PMCID:PMC4768404","volume":"25","author":"R Li","year":"2016","unstructured":"Li R, Yang D, Tang CL, et al. Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomography. BMC Cancer. 2016Feb;25(16):158.https:\/\/doi.org\/10.1186\/s12885-016-2156-x.PMID:26917546;PMCID:PMC4768404.","journal-title":"BMC Cancer"},{"issue":"8","key":"12970_CR22","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.3346\/jkms.2011.26.8.1023","volume":"26","author":"HS Park","year":"2011","unstructured":"Park HS, Bae JS, Jang KY, et al. Clinicopathologic study on combined hepatocellular carcinoma and cholangiocarcinoma: with emphasis on the intermediate cell morphology. J Korean Med Sci. 2011Aug;26(8):1023\u201330.https:\/\/doi.org\/10.3346\/jkms.2011.26.8.1023.","journal-title":"J Korean Med Sci"},{"key":"12970_CR23","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1007\/s00330-022-09131-5","volume":"33","author":"Y Xiao","year":"2023","unstructured":"Xiao Y, Zheng X, Zhou C, et al. Combined hepatocellular carcinoma-cholangiocarcinoma with a predominant HCC component: better survival and MRI-based prediction. Eur Radiol. 2023;33:1412\u201321.https:\/\/doi.org\/10.1007\/s00330-022-09131-5.","journal-title":"Eur Radiol"},{"issue":"1","key":"12970_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.7150\/ijms.50883","volume":"18","author":"Y Tang","year":"2021","unstructured":"Tang Y, Wang L, Teng F, Zhang T, Zhao Y, Chen Z. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis. Int J Med Sci. 2021Jan 1;18(1):187\u201398.https:\/\/doi.org\/10.7150\/ijms.50883.","journal-title":"Int J Med Sci"},{"issue":"6","key":"12970_CR25","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.ccell.2019.04.007","volume":"35","author":"R Xue","year":"2019","unstructured":"Xue R, et al. Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes. Cancer Cell. 2019Jun 10;35(6):932-947.e8.","journal-title":"Cancer Cell"},{"issue":"6","key":"12970_CR26","doi-asserted-by":"publisher","first-page":"e26233","DOI":"10.7759\/cureus.26233.","volume":"14","author":"E. K Proskuriakova","year":"2022","unstructured":"Proskuriakova E. K. Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: a literature review. Cureus. 2022;14(6):e26233.https:\/\/doi.org\/10.7759\/cureus.26233.","journal-title":"Cureus."},{"issue":"3","key":"12970_CR27","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1158\/1078-0432.CCR-21-1219","volume":"28","author":"CT Nguyen","year":"2022","unstructured":"Nguyen CT, et al. Immune Profiling of Combined Hepatocellular-Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy. Clin Cancer Res. 2022Feb 1;28(3):540\u201351.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"12970_CR28","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1111\/cas.15313","volume":"113","author":"N Yagi","year":"2022","unstructured":"Yagi N, et al. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis. Cancer Sci. 2022May;113(5):1564\u201374.","journal-title":"Cancer Sci"},{"issue":"1","key":"12970_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/hepr.13965","volume":"54","author":"T Ito","year":"2024","unstructured":"Ito T, Ishii T, Takeda H, Sumiyoshi S, Tomofuji K, Wakama S, et al. Comprehensive analyses of the clinicopathological features and genomic mutations of combined hepatocellular-cholangiocarcinoma. Hepatol Res. 2024;54(1):103\u201315.https:\/\/doi.org\/10.1111\/hepr.13965.","journal-title":"Hepatol Res"},{"key":"12970_CR30","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s00428-024-03792-x","volume":"484","author":"M Sasaki","year":"2024","unstructured":"Sasaki M, Sato Y, Nakanuma Y. Expression of fibroblast growth factor receptor 2 (FGFR2) in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma: clinicopathological study. Virchows Arch. 2024;484:915\u201323.https:\/\/doi.org\/10.1007\/s00428-024-03792-x.","journal-title":"Virchows Arch"},{"issue":"5","key":"12970_CR31","doi-asserted-by":"publisher","first-page":"766","DOI":"10.4254\/wjh.v16.i5.766","volume":"16","author":"M Vij","year":"2024","unstructured":"Vij M, Veerankutty FH, Rammohan A, Rela M. Combined hepatocellular cholangiocarcinoma: A clinicopathological update. World J Hepatol. 2024;16(5):766\u201375 10.4254\/wjh.v16.i5.766","journal-title":"World J Hepatol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12970-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12970-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12970-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T16:01:57Z","timestamp":1728316917000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12970-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,7]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12970"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12970-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,7]]},"assertion":[{"value":"16 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of West China Hospital. The Ethics Committee of West China Hospital agrees to waive informed consent because this retrospective observational study uses medical records\/biological specimens from previous clinical diagnosis, the risk of which was not greater than the minimum risk.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1232"}}